Drug Interactions between repaglinide and Tryvio
This report displays the potential drug interactions for the following 2 drugs:
- repaglinide
- Tryvio (aprocitentan)
Interactions between your drugs
repaglinide aprocitentan
Applies to: repaglinide and Tryvio (aprocitentan)
Consumer information for this interaction is not currently available.
MONITOR: Coadministration with inhibitors of CYP450 2C8 may increase the plasma concentrations of repaglinide, which is partially metabolized by the isoenzyme. In 12 healthy volunteers given the potent CYP450 2C8 inhibitor gemfibrozil (600 mg twice daily) for two days prior to coadministration with a single 0.25 mg dose of repaglinide on day 3, mean repaglinide systemic exposure (AUC) increased by 8.1-fold and elimination half-life (T 1/2) from 1.3 to 3.7 hours. When 160 mg twice daily of trimethoprim, a relatively weak CYP450 2C8 inhibitor, was given similarly in a study of nine healthy volunteers, mean peak plasma concentration (Cmax) and AUC of repaglinide increased by 41% and 61%, respectively, and T 1/2 increased from 0.9 to 1.1 hours. Another CYP450 2C8 inhibitor, deferasirox, given at 30 mg/kg/day for 4 days increased the Cmax and AUC of a single 0.5 mg dose of repaglinide by 62% and 131%, respectively. Further pharmacokinetic changes may be observed if there is concurrent inhibition of CYP450 3A4, which also contributes to the metabolism of repaglinide.
MANAGEMENT: Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, close monitoring for the development of hypoglycemia is recommended during coadministration with a CYP450 2C8 inhibitor. Patients should regularly monitor their blood sugar and learn how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation. The dosage of repaglinide may require adjustment if an interaction is suspected. Likewise, patients should be observed for potential loss of glycemic control following discontinuation of the CYP450 2C8 inhibitor, and the repaglinide dosage adjusted as necessary.
Drug and food interactions
repaglinide food
Applies to: repaglinide
Grapefruit juice may increase the blood levels of certain medications such as repaglinide. You may want to limit your consumption of grapefruit and grapefruit juice during treatment with repaglinide. However, if you have been regularly consuming grapefruit or grapefruit juice with the medication, then it is advisable for you to talk with your doctor before changing the amounts of these products in your diet, as this may alter the effects of your medication. Contact your doctor if your condition changes or you experience increased side effects. Orange juice is not expected to interact.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.